All articles by Swagath Bandhakavi
Swagath Bandhakavi
Genentech and Alnylam to launch Phase III ZENITH trial of zilebesiran
The ZENITH Phase III trial for zilebesiran, involving 11,000 patients, awaits regulatory approval and may start this year.
FDA approves Eisai’s subcutaneous lecanemab for early-stage Alzheimer’s
The regulator’s decision is based on Phase 3 data showing subcutaneous injections maintain benefits similar to intravenous dosing.
Health Canada approves Moderna’s updated COVID-19 vaccine for all ages
Moderna will produce all Spikevax pre-filled syringe doses for Canada domestically, with manufacturing in Quebec and Ontario.
Kite announces acquisition of Interius BioTherapeutics for $350m
The acquisition enhances Kite’s cell therapy capabilities by integrating Interius BioTherapeutics’ platform for direct in vivo CAR T-cell generation.
XtalPi partners with Dong-A ST for immunology drug development
XtalPi and Dong-A ST will collaborate on new treatments using a platform that integrates AI, quantum physics, and robotics.
vTv Therapeutics begins randomisation in Phase 3 cadisegliatin trial for type 1 diabetes
Cadisegliatin, or TTP399, is a liver-selective glucokinase activator with FDA breakthrough therapy designation.
Genmab’s phase 3 trial of epcoritamab yields positive results in follicular lymphoma
The trial met its dual objectives, significantly improving ORR and PFS, with a 79% reduction in disease progression risk.
Sun Pharma launches Leqselvi in the US for severe alopecia areata
Sun Pharma’s new oral selective inhibitor, targeting Janus Kinases JAK1 and JAK2, is now available for prescription throughout the US.
Imugene’s azer-cel shows promise in treating relapsed DLBCL
The company reported that six of seven patients reached complete remission, resulting in a 55% complete response rate.
FDA approves Lilly’s revised Alzheimer’s dosing regimen for Kisunla
The update introduces a new titration dosing method to reduce side effects without affecting amyloid plaque reduction efficacy.